The US Preventive Services Task Force has never evaluated a multicancer screening test for endorsement, which may make the process even longer, said Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco.
Patricia Deverka, MD, MS, senior researcher, deputy director at the Center for Translational and Policy Research and Precision Medicine, University of California San Francisco, talks about the 2 main paths for multicancer early detection (MCED) tests to be covered by Medicare.
Transcript
What needs to happen for MCED tests to receive an endorsement by the USPSTF and/or Medicare coverage? Do you think one path is more likely than the other?
The Medicare population is obviously a logical target for MCED tests, given that advancing age is a powerful predictor of increased risk of cancer. I think there's really 2 possible paths to Medicare coverage. One would be facilitating passage of new legislation that creates a specific screening exception for MCED screening tests, and the second would be to get a US Preventive Services Task Force [USPSTF] rating of A or B. That's a pretty long process—highly evidence-based—and it's worth pointing out that, to date, the USPSTF has never had to evaluate a multicancer screening test. The paradigm is typically 1 test, 1 cancer, so [the process comes] with all those caveats.
It's also important to point out that, regardless of either of those 2 pathways, both of those strategies would still require a national coverage determination before Medicare beneficiaries would obtain access through traditional Medicare. In terms of which one is longer, both paths have tremendous uncertainty. Because of the reason that multicancer early detection is an unprecedented testing paradigm, I think it's really difficult to predict which 1 of the 2 pathways is more likely to succeed, but hopefully I've pointed out how they're interrelated.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More